Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

25 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Symbyax Articles

Lilly's Symbyax is first FDA approved TRD drug

30 March 2009

Lilly's arzoxifene superior to $1.1B-a-year Evista in Ph III osteoporosis study

30 March 2009

Lilly adds warnings to Zyprexa and Symbyax

15 October 2007

US FDA to update black box warnings for young adults taking antidepressants

14 May 2007

Eli Lilly profit up 6% in 1st-qtr 2006

1 May 2006

Lilly swings to 4th-qtr 2005 profit

6 February 2006

Lilly swings to loss in 2nd qtr on settlement

1 August 2005

US FDA warns over off-label use of atypical antipsychotics

18 April 2005

New product launches in 2004

31 January 2005

Lilly sees sales climb 17% for 1st-qtr 2004

26 April 2004

US Rx drug sales up 11.5% in 2003, growth sustained by new products, says IMS

23 February 2004

UPDATE: Lilly's Zyprexa gets OK from FDA for new use

26 January 2004

Lilly's Zyprexa gets OK from FDA for new use

19 January 2004

Lilly provides 2004 guidance, says acquisitions will weigh on 1st-qtr

5 January 2004

Lilly drug cleared for depressive bipolar disease

5 January 2004

Showing 1-15 of 15 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
  • Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
  • Proposal to list Roche's Neulastim and Actemra in New Zealand
  • Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
  • Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
  • Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS